Medeze Group Public Company Limited
6.15
THB
+0.05
(+0.82%)
ISIN
THC430010007
Return %
Stock
S&P 500
1Y
-8.89
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
THB
•
in mil. unless spec.Working Capital
THB
•
in mil. unless spec.Growth Rates
THB
•
in mil. unless spec.Quarterly Revenue
THB
•
in mil. unless spec.Quarterly Earnings Per Share
THB
•
in mil. unless spec.Quarterly Dividends Per Share
THB
•
in mil. unless spec.Company Description
- CEO
- Veerapol Khemarangsan
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Nakhon Pathom Thailand
- IPO Date
- Oct 15, 2024
- Website
- medezegroup.com
- Similar Companies
- Business
- Medeze Group Public Company Limited is a Thailand-based biotechnology and regenerative medicine company that specializes in stem cell banking, cell isolation, cultivation, cryopreservation, and advanced cellular therapeutics. The company operates through several core business segments: Stem Cell Banking Services, offering collection, processing, and long-term cryogenic storage of hematopoietic stem cells and mesenchymal stem cells derived from umbilical cord blood, umbilical cord tissue, and adipose tissue; Hair Follicle Banking, providing the analysis, isolation, cultivation, and preservation of hair follicle stem cells under the Medeze Hair Renaissance brand for hair restoration; Immune Cell Services, delivering Natural Killer (NK) cell isolation, multiplication, and cytotoxicity potency testing; Biopharmaceutical and Advanced Therapy Medicinal Products (ATMPs), focusing on the research and clinical development of cell-based therapies for conditions such as osteoarthritis and skin degeneration; Cell Culture Media Production, manufacturing specialized media for biotechnology applications; and Commercial Healthcare Products, distributing dermo-cosmetics and nutritional dietary supplements. In addition, the company provides medical laboratory testing, cell viability analysis, and cellular research services. Medeze Group serves individual clients, medical practitioners, hospitals, and clinical research organizations across Southeast Asia, with operations and subsidiaries spanning Thailand, Singapore, Vietnam, Myanmar, Cambodia, and Indonesia. Founded in 2010, Medeze Group Public Company Limited is headquartered in Nakhon Pathom, Thailand. In recent developments, Medeze Group completed its initial public offering on the Stock Exchange of Thailand in October 2024 under the ticker symbol MEDEZE, raising capital to scale laboratory infrastructure and research operations. As part of its strategic shift from a biobanking model to an integrated biopharmaceutical enterprise, the company established GPO MEDEZE Empower Co., Ltd., a joint venture with the Government Pharmaceutical Organization of Thailand and Cretan Associates, capitalized at 105 million Thai baht to construct a GMP-certified domestic manufacturing facility for cell culture media and ATMPs. To enhance production sterility and throughput, Medeze Group integrated automated robotic cell culture systems developed in collaboration with Shibuya Corporation of Japan. Additionally, the company was selected as the exclusive private-sector partner in the Ministry of Public Health of Thailand ATMP Sandbox program, supporting the regulatory development and commercial translation of novel regenerative medical treatments.